{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:51:04Z","timestamp":1783468264914,"version":"3.55.0"},"reference-count":38,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec id=\"S0007125017000216_sec_a1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is little evidence to guide pharmacological treatment in adults with Down syndrome and Alzheimer's disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125017000216_sec_a2\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the effect of cholinesterase inhibitors or memantine on survival and function in adults with Down syndrome and Alzheimer's disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125017000216_sec_a3\" sec-type=\"methods\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This was a naturalistic longitudinal follow-up of a clinical cohort of 310 people with Down syndrome diagnosed with Alzheimer's disease collected from specialist community services in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125017000216_sec_a4\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median survival time (5.59 years, 95% CI 4.67\u20136.67) for those on medication (\n                      <jats:italic>n<\/jats:italic>\n                      = 145, mainly cholinesterase inhibitors) was significantly greater than for those not prescribed medication (\n                      <jats:italic>n<\/jats:italic>\n                      = 165) (3.45 years, 95% CI 2.91\u20134.13, log-rank test\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001). Sequential assessments demonstrated an early effect in maintaining cognitive function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125017000216_sec_a5\" sec-type=\"conclusion\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cholinesterase inhibitors appear to offer benefit for people with Down syndrome and Alzheimer's disease that is comparable with sporadic Alzheimer's disease; a trial to test the effect of earlier treatment (prodromal Alzheimer's disease) in Down syndrome may be indicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125017000216_sec_a6\">\n                    <jats:title>Declaration of interest<\/jats:title>\n                    <jats:p>A.S. has undertaken consulting for Ono Pharmaceuticals, outside the submitted work. Z.W. has received a consultancy fee and grant from GE Healthcare, outside the submitted work.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.2017.21","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T04:32:41Z","timestamp":1519792361000},"page":"155-160","source":"Crossref","is-referenced-by-count":39,"title":["Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study"],"prefix":"10.1192","volume":"212","author":[{"given":"Nicole","family":"Eady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bohnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Courtenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Gazizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"McBrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalika","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Perez-Achiaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Strydom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"S0007125017000216_ref6","first-page":"CD007656","article-title":"Galantamine for dementia in people with Down syndrome","volume":"1","author":"Mohan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125017000216_ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0109-2"},{"key":"S0007125017000216_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt119"},{"key":"S0007125017000216_ref37","doi-asserted-by":"publisher","DOI":"10.1352\/0047-6765(2000)038<0276:PODAIO>2.0.CO;2"},{"key":"S0007125017000216_ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109484"},{"key":"S0007125017000216_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05285-4"},{"key":"S0007125017000216_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3821"},{"key":"S0007125017000216_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08092-3"},{"key":"S0007125017000216_ref7","first-page":"CD007658","article-title":"Rivastigmine for dementia in people with Down syndrome","volume":"1","author":"Mohan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125017000216_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7"},{"key":"S0007125017000216_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht182"},{"key":"S0007125017000216_ref12","volume-title":"Dementia Questionnaire for People with Learning Disabilities (DLD)","author":"Eurlings","year":"2006"},{"key":"S0007125017000216_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.09.015"},{"key":"S0007125017000216_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3983"},{"key":"S0007125017000216_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.1992.tb00532.x"},{"key":"S0007125017000216_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2009.01158.x"},{"key":"S0007125017000216_ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35706"},{"key":"S0007125017000216_ref11","volume-title":"Dementia and People with Intellectual Disabilities","year":"2015"},{"key":"S0007125017000216_ref35","volume-title":"Dementia: Supporting People with Dementia and their Carers in Health and Social Care. CG42","year":"2006"},{"key":"S0007125017000216_ref5","first-page":"CD003154","article-title":"Memantine for dementia","volume":"2","author":"McShane","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125017000216_ref16","volume-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"S0007125017000216_ref27","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.7.1133"},{"key":"S0007125017000216_ref8","first-page":"CD007178","article-title":"Donepezil for dementia in people with Down syndrome","volume":"1","author":"Mohan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125017000216_ref10","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4228"},{"key":"S0007125017000216_ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12074"},{"key":"S0007125017000216_ref4","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125017000216_ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3148.1997.tb00006.x"},{"key":"S0007125017000216_ref17","doi-asserted-by":"publisher","DOI":"10.1002\/0471458546.ch4"},{"key":"S0007125017000216_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61676-0"},{"key":"S0007125017000216_ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130993"},{"key":"S0007125017000216_ref23","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181e56d30"},{"key":"S0007125017000216_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1306"},{"key":"S0007125017000216_ref36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.1.143"},{"key":"S0007125017000216_ref29","doi-asserted-by":"publisher","DOI":"10.1002\/gps.587"},{"key":"S0007125017000216_ref38","unstructured":"Cleves , An Introduction to Survival Analysis Using Stata, Revised Third Edition. College Station, Texas: Stata Press, 2016."},{"key":"S0007125017000216_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115101"},{"key":"S0007125017000216_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.10.003"},{"key":"S0007125017000216_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4371"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125017000216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T15:55:28Z","timestamp":1555343728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125017000216\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0007125017000216"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2017.21","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732771286.793544758","asserted-by":"object"}]},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]}}}